Entry of Protein Subunit Technology into the European Market

The European Medicines Agency (EMA) has granted Conditional Marketing Authorization (CMA) for Nuvaxovid (NVX-CoV2373), Novavax's recombinant antigen-based COVID-19 vaccine. This marks the first protein subunit-based alternative to be introduced into a market previously dominated by mRNA vaccines such as Comirnaty (Pfizer-BioNTech) and Spikevax (Moderna). It is expected to play a crucial role in addressing vaccine hesitancy and providing a safe and reliable option for individuals concerned about the side effects of mRNA vaccines. Notably, this platform follows traditional manufacturing processes used for influenza vaccines, making it highly acceptable to the public.

Robust Efficacy Demonstrated Based on Phase 3 Clinical Data

Nuvaxovid demonstrated an overall efficacy of 90.4% in preventing infection in the PREVENT-19 Phase 3 clinical trial, which involved 30,000 participants in the United States and Mexico. Furthermore, a Phase 3 clinical trial conducted in the United Kingdom also showed a high efficacy of 89.7% in preventing infection, confirming its statistical significance. The vaccine demonstrated 100% efficacy in preventing moderate to severe disease in both trials, indicating a high level of protection. Common side effects included pain at the injection site, headache, and muscle aches, most of which were mild to moderate and resolved within a few days, confirming good tolerability.

Securing Commercial Viability and Financial Value through Advance Purchase Agreements

With this approval, Novavax can now fulfill the advance purchase agreement (APA) with the European Commission for up to 200 million doses, opening up commercial opportunities. The agreement includes an initial supply of 100 million doses with an option for an additional 100 million doses. Industry analysts estimate the deal to be worth approximately $20.90 per dose. This translates to a potential financial revenue of up to $4.18 billion (approximately 5.5 trillion KRW) for Novavax (NVAX). This significant influx of cash is expected to provide crucial liquidity for the development of next-generation vaccines against emerging variants and combination vaccines for influenza.

Advantages of Refrigerated Storage and Changes in the Global Vaccine Distribution Market

Nuvaxovid has a key advantage over mRNA vaccines, which require ultra-cold chain logistics (at temperatures as low as -70°C), as it can be distributed and stored at standard refrigerated temperatures (2-8°C). In a highly competitive market where Pfizer generated $42.69 billion and Moderna generated $25.71 billion in vaccine sales in 2022, Novavax's strength will be a significant differentiator in regions with weak distribution infrastructure or in smaller hospitals. Ultimately, Nuvaxovid is expected to lead the diversification of the global vaccine supply chain and serve as a pivotal milestone in resolving structural bottlenecks in the vaccine market.